BRISTOL, Tenn. & MENLO PARK, Calif.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE: KG) and Depomed, Inc. (NASDAQ: DEPO) today announced the launch of a new program that will provide support for patients with diabetes who are receiving treatment with Glumetza™ (metformin hydrochloride extended-release tablets), a new once-daily extended-release metformin formulation that features AcuForm™ drug-delivery technology.
